SRRK - Earnings call transcript Q2 2020 | Scholar Rock Holding Corporation

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Scholar Rock Management Intro and Second Quarter 2020 Financial Results and Business Progress Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions] I would now like to hand the conference over to your speaker today, to Catherine Hu, Vice President, Investor Relations and Corporate Communications. you. Thank ahead. go Please

Catherine Hu

appointed Events thank an joining XXXX update as of our as and and Tony call and CFO financial on to well Head newly to introduction provide on Operations; an and you morning, CEO, us Kingsley; Ted for Business today's results President Good second quarter on of can Chief webcast slides The Investor our Chyung, also be Yung on Rock call. on Officer, will the section be website. this today's call and joining Relations page Myles. Medical Tony the accessed the and Presentations Ted Scholar for

it to Rock's making turn various I that expectations, wanted Before be today's Scholar about prospects over statements. future to during note forward-looking that statements will plans I we call, and Tony, constitute

and should views Securities as Rock's represent statements required We to Tony. date. filings to statements of Private in will fully any Commission. of well obligation as turn from update I materially our a statements in Form the our in you our under as XXXX. result relied provisions quarterly now be by Scholar important of Act report of on other purposes forward-looking forward-looking Any Securities or entitled unless Reform of future today forward-looking indicated Rock's harbor Exchange actual and as any discussed may XX-Q the Scholar future various as upon the with the factors the Factors law. by and important section any call safe the representing Risk results Litigation those differ not For as factors, only views disclaim over Thank any

Tony Kingsley

are science new it Scholar an The joining and inflection readouts, has Catherine, next you, programs prove to clinical moving morning. everyone, company's for leadership to is quickly toward at to data this and company the beginning potential multiple phase. our thank the its Rock utility, point. Thank us is you, take

why I at have about myself time. tell a you and this Rock joined me Let little Scholar

a Slide oncology President was that at acquired described Bio, was most stage development X, Taris of Pharmaceuticals of As company, recently XXXX. end Janssen on I the and CEO by

as I rapidly life operations Taris, to this to becoming The experience This and that transition critical sciences Company, planned was that, extensive years, Scholar that CFO founding our I Board of knows Medicines Ted Nagesh. Before also drug Myles in in to times Biogen. almost seeking about both replace of CEO, served Ted immediately for was Board fact the confidence the transition, commercial should leadership signals to at have I and Operations Head strategic able future. later-stage that of Scholar Rock bring signal operational to you President on of was great well. success. very and to profile are and served as is nearly has and Rock's X in the bring both headed growth. our I and a company and And companies our success. transition it which is commercialization, building and on Business the and COO for purposeful the I That prior provided development

shortly. You from will hear Ted

targets commitment been into to Rock: as I execution powerful impressed great me and fully me Scholar and practice the what people. neuromuscular take the talented immersed the of changing and to Now on and collaboration science, medical helping on programs suffering of has only My describe culture cancer increased and work programs let goal drew from company. patients as conviction platform the we the of and towards scientific I've level with tough disease.

top in scientific programs platform significant the has produced therapeutic X Now our potential. to presentation. with takeaways multiple first, Slide three My going are:

highly pipeline join program's address markets milestones, well-developed points in and and diseases. and both SRK-XXX programs, productivity key reporting value quickly be elucidate well fourth factors advanced our There to and clinical captures the and atrophy, I my talented our multiple most The power see or at believe slide the as and very as that of II rapidly. ongoing in growing depth multiple potential and help we quarter, that are will trial And this patients breadth over two of near the scientific demonstrates illustrates Our that followed significant To SRK-XXX optionality. I you The programs SMA, SRK-XXX long-term offers Scholar It clearly are X, Scholar data start as multiple growth with quickly, XX-month can see of on are with potential. Phase drove and that and serious toward next months Slide well-designed. science are inflection interim differentiated. results platform advancing from will to Rock's programs the the XX the the are scientists. also muscular is in by half moving strategic spinal XXXX. first milestones each decision Rock. we TOPAZ will our

SRK-XXX Our by therapy the to establish muscle-directed goal as first SMA. here is affected for patients

in we're Phase on backbone the DRAGON Next progress therapeutic potential building I cancer to SRK-XXX, a immunotherapy. momentum rapid trial making for

study of next inhibitors, in the We update we on have checkpoint the believe Part the We unlock key to advancing combination we'll quarter. are quarter checkpoint to an better in inhibitors. and AX the power unlock to to this with SRK-XX provide the escalation dose of evaluate

that and change which an We only increase has the to checkpoint isoform, to patients across SRK-XXX company types. adverse inhibitors medical response to are the specifically efficacy potential tumor potential believe TGFßX to solid multiple rates the We target the and improve immense cancer care for events. minimizing first has of while we believe risk

potential it's our extend collaboration is progress additional another important approach. This growth with and started. addition proof In two we or well. to which And clinical of attractiveness treatment there furthermore, partnership the settings, whether to have us types fibrosis, additional continues factors are point additional many these around on assets, our science, an our indications, platform tumor Gilead to opportunities or for

Yung? So with Yung that, will Medical over Chief Officer. our it I turn to Chyung,

Yung Chyung

welcome I this extend to an progress across to warm today, Thanks for the our making Ted. to everyone another want us update we and provide are call to Thanks, of on all Tony. excited development I'm great on very joining you programs.

clinical First, level of the study I high want say commitment to investigators how I sites engagement team's programs advancing and am of despite from we clinical dedication the are how proud the COVID-XX pandemic. and our of appreciative the to ongoing our challenges trial of and

advanced with strides inhibitor monoclonal for a readouts and great candidate, important activation make the SRK-XXX our SRK-XXX which is human product and SRK-XXX, a the of to most continue highly latent both and antibody fully towards pro program. We Starting of myostatin. specific

the first muscle-directed clinically increase as promote SRK-XXX in establish to is meaningful therapy motor function for goal a potential to SMA. patients Our with

but SMA therapies we two therapies. landscape the classified distinct SMN As outlined upregulator seven, being on as therapeutic and muscle-directed treatment Slide into complementary strategies, view

of therapies, SMN prevent in Over therapies, the known past few aimed corrector which years, motor addressing as the at the are there SMN deterioration. have to order in neuron upregulator deficiency been further also development advances SMN

as at have progress, Even continue to of therapies, be disease onset for of This mean such nusinersen SMA, beyond of a in unlikely. green. Patients months category CHERISH HFMSE, needed the While the III disease of complete namely such to with from function. of to represents believe stabilize therapy, expanded baseline aim treated course. right-hand on absolute Motor in advent in important shown slide. to from manifestations as motor is driving a an the with of later for to the impairment go experienced once points motor by Functional correction appears muscle-directed we need improvement is therapeutic data Therefore, is highlighted the advances benefit invention, Scale, approach or side nusinersen function improvements of X.X Hammersmith the their primary XX shown early therapies trial individuals upregulators as SMN that Phase the second on

the the patient treated of result right-hand as Slide a motor at viewed by between SMA eight, X area. evident phenomenon compared was shown in function still scores be is clinically given gray in A with X of as look improvement this slide. that observed motor older with to even a the predominantly favorable is patient patients XX A in experience aged considered to endpoint and non-ambulatory stabilization, SUNFISH there XX, nusinersen disease. motor the of is a the this at XX% room were primarily improvements of over patients a outcome able a the young improvement, clinically deeper very treatment. Type who of In While and in occurred the depicted score different in to improvement scale, CHERISH certainly patients the is were to Type a of it and score, the Taking months The appear than usual as on use in trial as Hammersmith or initiation X treatment. course widely less of contrast, X-point XX similar in with stabilization time Hammersmith gradient MFMXX primary trial months nusinersen very five at in trial on the a for who ages risdiplam achieve significant of age. least function the function X-point meaningful meaningful, at side

was placebo, treatment and advance all disease improvement. function not upregulators point obtain primary stabilize as stabilization mean was To improvement five which met, over prevent motor neuron endpoint a significant. was which observed did across SUNFISH SMA endpoint, motor patients statistically important deterioration of phenomenon the the patients represent in in further the trial showed HFMSE in agents most not While X.XX over also this an age these the SMN X-point of reiterate, the a course. This secondary

of set SMA improvements. motor next development the for seeks the Now drive is function to era that stage drug

as potential this SRK-XXX muscle-directed trial. we now backdrop, to II turn and attention the in the has With SMA SRK-XXX our become of the to believe ongoing upregulator. SMN backbone to let's Towards any be potentially a and TOPAZ the Phase therapy that vision, first treatment

progress X. towards outlined We of SRK-XXX, therapeutic on as Slide investigating path the the potential have substantial made on

in strong investigating blockade myostatin translational have We formulated a for SMA. rationale

We preclinically Delta SMN therapeutic effect model. the X Mouse have in demonstrated

We trial and in myostatin. dosing healthy that the trial the Preliminary PD the the in data in data showed latent of TOPAZ TD evaluating regimen volunteers this are from form trial; completed the TOPAZ of a as engagement that have demonstrated target supports Phase we well. every-X-week robust SMA a patients of with that engagement adult I importantly, confirm safety; PK profile SRK-XXX, target initial

and are We on expected path efficacy look and to in forward the interim analysis quarter. the safety the fourth development along far SRK-XXX for

XX. Phase of non-ambulatory XX short, some subpopulation SMA. of before These XX treatment patients XX with patients upregulator patients X for Functional study with conjunction evaluating weeks total very age. are and distinct used the and assessments to SMA, previously aged who ages patients Turning Hammersmith of tailor the the Type expanded with X to of X outcome a ages Type initiated with every parallel with for with received Hammersmith in for SMA. non-ambulatory patients Scale, modifications clinical patients clinical X and ambulatory the trial the are approved a planned an approved older, SRK-XXX X X X for as At enrolled study SMA, review X with patients III upregulator. Phase endpoint a with Cohort Revised or designed primary the also are of either between HFMSE, patients the TOPAZ year, is RHS dosed is RHS The with or is in each Type between study and Cohort SMN II this all consists an an enrollment XX, This X Type beginning XX and Type X approved we Type XX or SRK-XXX in completed monotherapy conjunction specifically, Cohort X enrolled X SMN treated the treated patients enrolled upregulator. the SRK-XXX, of to More as X design. Slide the and of are had with Motor SMA U.S. efficacy in of Europe. X used the similar years SMA, research, efficacy to validated or SMA, TOPAZ HFMSE in evaluated IV endpoint to to Scale, nusinersen. All often in in SMN ambulatory. The and the CHERISH trial XX The served months. who and ambulatory practice a and in of the short, X and primary specifically HFMSE of be cohorts, measure

Let's for and analysis, our the interim the X-month now quarter expectations to of walk we disclose which through receive this in year. fourth expect

on efficacy with XX. and Slide Cohort readout planning looking across are X safety a We endpoints. for Starting robust

We will can improvements be rather baseline stabilization. lead treatment to from if over Hammersmith in motor merely than looking just evaluate Scale at indeed the baseline in function absolute Revised change SRK-XXX mean to

We X-point patients clinically widely individual will RHS in patient a a X-point in unexpected is meaningful. also in over of To given also be least evaluate improvement the reiterate, achieve to proportion improvement most and considered a at baseline. to be patients would

In such timed be walk addition will run, timed and also rise to from we walk test, at floor. and tests, looking and RHS, X-minute the as motor XX-meter

is While in our any impact. to that this be SMN to would will interesting the effect of base may it see assumption correction monotherapy SRK-XXX be an if SMN through have necessary patient SRK-XXX upregulator population, complement

X-point least and be looking also X, in Cohort mean proportion in individual HFMSE from retain a baseline. over of at baseline HFMSE, evaluate will we'll the the For we at improvement change patients

including of patients by of module, benefit Cohort development a be meaningful X a RULM dose the to efficacy. seeing in evaluating and on X. if initiated the in outcomes, population Health lower nusinersen limb were or upper SRK-XXX milestones. before also who still younger this in offer short, cohort enrolled dose investigate age will exploration the may Organization potential conducting World additional motor We patient revised We're

lead We in to looking see will can to be substantial treatment a a HFMSE. improvement

will of course arms, X such the differentiation effect. addition, be therapeutic between In for effect dose as potential time in therapeutic the of onset we exploring

RULM evaluated Additionally, motor patients will be and developmental WHO on milestones. the

different note SMA cohorts, us enthusiastic are the that a for in which is wider in of SMN are patients unmet cohorts subpopulation, high sizable of a a about or encourage us via approved demonstration would whether any we upregulator. broaden potential any cohorts The combination number proof-of-concept to X there X range therefore, population and of we evaluates all While and medical there would, to of these need. broader an SRK-XXX each SRK-XXX's result should X X to also subsequent investigation be the important age patients, with of of

In fiber of successful X the would validate in result addition, SRK-XXX's any hypothesis other positive Furthermore, further patients Type potential role. support motor deficits play us efficacy of investigation cohorts Cohort early a setting, X, evaluate intervention presymptomatic or disorders fast-twitch key outcome across potential the the which in therapeutic a proof-of-concept we of function and SMA in to SRK-XXX individuals. the therapeutic believe a would neuromuscular that X building as for SRK-XXX such with encourage

TOPAZ efficacy I just that to SRK-XXX, from everyone we patients want treatment to are with while the all turning active Before remind receive SRK-XXX trial, data. in firewalled the

the are We quarter. to in you fourth the and results sharing eager look forward to with see data interim the

X, extension have the As X elected the XX-month note, completed enroll who as to a final August X entire XX-month of voluntary have the patients treatment, study. all in of

cancer therapies potential our era highly which a and inhibitor response TGFßX, Now inhibitor has to believe SRK-XXX, may discuss immunotherapy. new the to of checkpoint of backbone let's selective of the we be increase

XX. Slide to Turning

treatment patients. the therapeutic revolutionized effective only a in of approach is cancers, approximately have this of of inhibitors XX% checkpoint While wide range

is XX, central what immuno-oncology response As mounting in and primary anti-PDLX in as to to the key of is in question science anti-PDX that arena culprit a TGFßX driving in the highlighted driving and So the inhibitors evidence therapy. implicates fast this on moving lack patients? most checkpoint resistance is Slide is,

fragment urothelial identified that increased the an inhibitor and levels with tumors checkpoint checkpoint an to TGFß the cells nerve say, to observation response excluded as failed around a in been survival less emerging effectively These accumulate be of to at signaling of with well TGFßX that Mechanistically, industry. in tumors well-known in tumors attention therapy outcomes example, immune association similar made but researchers into carcinoma. as reduced And Genentech tumor was excluded the is respond been to observed this therapy. tumor by captured For between the phenotype, patients to insights driving immune infiltrate lack likely inhibitor in have T to have peripheral which phenomenon. implicated has

KGaA And and PDLX. modulate Tilos commercialize and jointly bispecific Just global anti-PDLX both antibodies Merck a acquired and last molecule or Merck TGFß. GSK TGFß alliance to to develop that announced Therapeutics and develop that -- year, targets a

solid Slide As resistance of different inhibitor cancer. TGFß Earlier overcoming a towards the the XX, exhibit most in therapeutic of may a predominant types substantial year, we, proportion human delineated detailed isoform of TGFßX potential checkpoint excluded of tumors an was that phenotype. tumors. blocking immune And solid found many tumors TCGA ourselves, be broad of through the on analysis the aim publication conducted across an and this isoform that database, immunity

overcome thus, TGFßX, rates has the the increase therapeutic hypothesis emerged. has to to the checkpoint therapy potential particularly Blockade has of And approach combination now substantially inhibitor So an immunotherapy. potential exciting resistance. to this TGFß, response

Slide and SRK-XXX targeting whether latent or isoform. for several and potential Turning no through trap, may with the molecules. to its the and the ligand TGFßX offer XX. for human targeting binding nonselective of or avoiding latent to increase offers pathway. therapeutic activation antibodies fully monoclonal TGFßX Because with by a selectivity to potentially the bispecific unique through the antibody toxicities to or TGFß, SRK-XXX to TGFßX TGFßX associated of isoform, window bind to TGFß There inhibition. small are is nonselective minimal approach optimal approaches a TGFßX designed the believe latent We to SRK-XXX a

well combination given inhibitor indications of each suited the checkpoint a individual for dosage as than component enabling offer optimization enabling In linked a advantages with aptly SRK-XXX physically that having as tumor the a more of distinct a therapy. could for of may as be addition, bispecific inhibitor, over pairing be with approaches we checkpoint agent by molecule view an rather potentially anti-TGFßX

inhibition the potential the toxicity the XX. in immuno-oncology nonselective pivotal implicating against checkpoint Momentum in the robust field we with dosing significant window strong. scientific the positioned continues have to that body is of is those investigating well in multiple grow. pathway, mouse we observed for Turning preclinically, and inhibitor models. targets. pursue to for this of investigate overcome And in more to permit and TGFßX's the combination leads rationale potential TGFßX TGFß, therefore, believe a to associated the is pathway The to greater SRK-XXX exciting with TGFßX selective offers potential and role program therapy inhibition responses our of The tumor therapeutic resistance SRK-XXX SRK-XXX of is There anti-PDX a inhibition accelerating, therapeutic evidence in Slide antitumor to hypothesis.

to investigators on Phase trial dosing of the pandemic. let's the turn the in against the Now second engagement of are of encouraged I trial the the and the pace DRAGON progression, this commenced backdrop the in XX. trial Slide by We quarter trial and particularly COVID-XX

SRK-XXX will look with of the walk evaluate the the potential dose DRAGON trial. portion The the part locally Part antitumor for a expansion as significant some is trial at is anti patients in The The escalation as a B Slide tumors, will dose of therapy readouts. trialists, or activity SRK-XXX monotherapy of evaluate in comprised A anti-PDLX drew trial which trial solid or advanced enrolling the detailed clinical cords. input of of of metastatic combination safety and efficacy and and with X or trial frequent X in and Let's highlights which through thought parts. early part well the the parallel offers more A provides oncology DRAGON and design, tumor therapy. of as anti-PDX leaders XX upon with PD-LX from portion anti-PD-X combination

in AX a dose SRK-XXX escalation been trial. part have We the as of advancing agent single of

staggered therapy. AX dose evaluate AX with AX escalation to to a a this expect trial and follow AX plus of of quarter the the SRK-XXX anti-PDX initiate designed Part anti-PDLX Part trial combination or will Part in Part in progress fashion, are we design. X As to X

early the history anti-PDLX subsequently combination documented single. with a evaluating upon for is with primary addition resistance, is enrolled anti-PDX this SRK-XXX, treatment would to have to given defined of time an each to efficacy could at portion focus there illustrate, a patient potential response on lack attributed expected not While be on result of a the to response To inhibitor of a have and any of will of have safety observing course antitumor patient of If therapy. study consistent SRK-XXX. checkpoint the clinical that the SRK-XXX, or be by goes the

relatively we with observe result, could even patient a numbers. potentially signals efficacy As small

Part patients Slide This in Moving types. the combination to potential or anti-PDLX on XX. resistance enrolling parallel multiple of to to with trial of X B tumor with will across primary each checkpoint anti-PDX therapeutic SRK-XXX solid therapy inhibitors cohorts, evaluate XX DRAGON the consist to of up

across primary who non-small we who we attributable resistance with either potential for patients believe addition following nivolumab. signals lung multiple Part to this For primary we proof-of-concept we combination if of responses the to melanoma, SRK through will multiple antitumor demonstrated path treatment enroll opportunities enrolling the design for urothelial cell therapeutic And for types. cancer a with resistance effect have planning SRK-XXX, observe B carcinoma, then rapid be Again, patients and efficacy to pembrolizumab. believe pembrolizumab tumor have We or may allows be are XXX. to shown

an towards of with the registration. inhibitors, need context the high path could development Given longer-range in also checkpoint support patients primary proof-of-concept goal drug a strong resistance efficient to of unmet signal the

B pleased the are pandemic, are expeditiously. year moving of ongoing are the in update Part antitumor safety of planning in in efficacy We to with the escalation first started impacts We the trial. XXXX, Despite quarter provide this progress the COVID-XX to plan in XXXX. dose on fourth this expected an progress starting with to data we date initiate and XXXX, in and quarter

from and investigators care well all work participating staff, suffering our Before individuals Ted, to our trials. medical clinical Ted? achieving transforming Together, the as it hope I towards of as can our in I to patients turn the we I aspiration team, want and site for study thank SMA over cancer.

Ted Myles

from next so I time trial Scholar nearly quickly, the is clinical Yung Scholar and to the executive the can clinical a rest by therapies of us operational I and the lead The last Rock dynamic had help of year, strategic forward company platform, to I to Head months ability our we a advancing we plans. me of the start in partnering month. away honor of if executive Rock. late-stage Scholar have as Tony, Like Rock's our positive, stage two on feedback and the decision the to look This Yung. degree planning that confidence advance of before could broadest to why at for are set a clear you, and to growing biopharmaceutical clinical the our Operations programs. as company I view I'll Board join just serving Directors team's execute. Business need. important a ambitious the into Ultimately, describing team gave and to the long-range Furthermore, years of potentially my Tony, high some scientific to Rock. joining Thank readouts, many apply senior patients in with subject expertise begin is important early Scholar data which, and execute CFO accomplishments is and programs made This excited of also the a for as initiating why authorities. commercial regulatory clinical we the necessary from to as and registrational financial I'm is commercialize goal companies as to

financial This the advancing antibody in services. can ago. trial, and a was about the the Net for of and to the per To to costs higher expense SRK-XXX to quarter was the clinical loss share and related a the GAAP quarter XXXX half on prior result R&D was compared library, loss quarter ambitious for second exclusively quarter. of Specifica the and stage the to to Revenue let's approximately delivery $XX costs. net with The well professional second a $X focused as the capabilities Gilead collaboration. in more million, year-ago plan as can $X or support to approximately platform per was first products quarter expanding acceptance year-over-year Now highlight in million compared our a year million $XX year in was personnel-related the G&A XX and in second approximately investing the to for of to customized $XX primarily G&A was for and quarter TOPAZ research $X was discovery our that generate loss million increase This summarize, of attributed expense payment a ongoing future, results. million the be Slide personnel-related share. clinical million display million just turn increase quarter. year-over-year on our of our for ambitions $X.XX programs, $X.XX with $XX.X is R&D and net the about aligned investing our development quarter spending many with for compares infrastructure. to

at marketable the securities XX, As of million XXXX. end $XXX cash $XXX million and of of approximately June versus XXXX, we had equivalents cash and

our the points operational continue pipeline. current believe my platform, the up of that to we'll scientific drug plan a we wrap extends and we XXXX. fourth feed that to have a Our To productive efforts runway invest discovery into quarter comments, to

cancer lot invest patients. in. the and of moving indications. clinical towards on terms in quickly it believe important is cusp as And We is landscape to of data, immense many Simply, has to us on lot SRK potential on clinical top a SRK-XXX value-creating change going the well clinical a treatment milestones. is of have optionality ongoing programs, programs we two trials. great there of for these for as have next we

Tony remarks. it closing turn for Now Tony? some to back I'll

Tony Kingsley

To filled of Slide our platform. XX, scientific made, six potential important backdrop the elucidate the R&D this am say to milestones close, our especially and you, want Thank to number how to a next of ongoing against with I will continue with pandemic. Ted. impressed company Coming has programs I the the that the progress quarters of back are

want updates We that are both forward I'm on scientific on we take very to are quarter. the I from our work targets can support awaiting to thank morning. much of I confident their some thank benefit. their also SRK-XXX many our my the toughest get our And more in to that colleagues for patients dedication patients therapies. providing hard fourth medicines the and of this who want platform, and based SRK-XXX with looking time so and achievements shareholders to And our with

operator. can I think to turn Q&A, now we

Operator

Thank you, go our line Please question first ahead. the Instructions] from of show [Operator Jefferies. Michael comes from sir. Yee I

Michael Yee

Tony, Hi new thanks good role. on morning, congrats, and guys the

the forward that this. lot youngest two Yung. study. But greatest Looking CHERISH patients. On with group Cohort of a you in you questions see also given most group, see the would in think XXX, that Maybe you X could the be improvement to for might Spinraza effect the

then delineate So how you just your a groups? words, maybe and And expectations you so are think we're and about X? Cohort data you expecting you delineate XXX other versus do you and see improvement how later on X escalation Thank doses Cohort between low going much. that responses see to in even those X In could at actually TGFß, you dose this X-point year? could in

Yung Chyung

yes. Mike, Hi,

right? evidence background nusinersen with older Cohorts age thinking context in expectation five cohorts, absolute various efficacy five stabilization, X, function and stabilization X yes, -- or disease be certainly, discerning aged for starting the than would started about it's the question that the So older, about the first primary and indicates gains. of that your rather and so patients Motor

as zero-point than rare baseline of now what But there rather from baseline that an XX% motor in in improvement, see sizable to see achieve achieve at So change III that risdiplam, patients will be it's patients there trial. from for to least a such for improvement the given that a improvement look what than Phase trials well CHERISH proportion going is in indicate individual nusinersen change analysis in the absolute a the mean to we're less as key function from as data X-point so context.

So it would from a think expected in otherwise if or we X-point in would an be exciting That substantial of proportion a be SRK-XXX consistent greater improvement patients would course. achieve baseline.

do stabilization. out, at you motor X, young patients point are some age before X, -- baseline. Cohort nusinersen they just function for the Now i.e. on It's age not who of age, see improvements over as started

dramatic to substantial which generally looks it's as to strategy we're the amount terms with upon a so effects And the of there's low-dose see to analysis motor offer just this too we'll arm doing right, any then well curve the WHO well upper It's like X can And is indicating in arm. the of improvements measures rapid, differentiation not exploration, such there terms just Cohort nusinersen, time can over part as you right? this efficacy very data function, just if may improvement, as observe a we're dose the now if the of dosing both that that effect, some So milestone. as because what for what the inform look that. see high-dose in arms, there's We're going improvement of because in in X other a dose, improvement key and as outcome what we're addition, nusinersen. the in looking steady course an the is as like looking revised in above finally, on time, of like you then directive future. on for motor see limb between might there's track such And module

a improvement gain. milestones, achieved only see approximately WHO bar a milestone WHO to side, high not CHERISH motor and effects X the As very they XX% milestone motor nusinersen that's efficacy. do show a study, the on in in Even reminder, on significant

to I I really at it's Cohort SRK-XXX therapeutic checkpoint So is advantage context checkpoint is there regards sizable Mike, in variety about different at The with to multiple looking from numbers. ways we're on different escalation, that combining efficacy resistance. With there's in population where experienced potential your for of base the types top think think for with of Part a X to looking SRK-XXX really explore assumption dose our of effects question, inhibitors. evaluate nusinersen. of looking going tumor where primary efficacy B have the a patients we're inhibitor for We're

prior it's numbers, Because exciting, checkpoint start each in efficacy, right? relatively history have So you would the to not combination, patient resistance. if given now seeing otherwise small inhibitor a be clinical response expected of even

be that. we'd So from excited

Part This more with are surprise. an look explore I of potential going upside to Now yes, would efficacy. for pleasant A, we mean, be and

because again, in what what going see dose have in just inhibitor, we Part we're in who the happens like didn't continue where B take is have do in know, signals. the right, but track to really for opportunity checkpoint look to a to study our But the oncology, to happens now and Part escalation. think, combination. efficacy is expectation advantage it's I see as a see base going to is possible, But response, if are again, we we're tried you look patients there and AX, can population

Operator

BMO Our comes Kim next Do question from Capital. from

Unidentified Analyst

on on us. Jameson is This XXX Do. from for Two

be of for one then bit a you for how First that year-end? of elaborate us XXXX? second expectations biomarkers maybe. will patients, that little readout the on And data we in as a type Yung. the that The and interpret question read-through on for should Tony presented by for Could amount potential full more

large that market, tumor going targeting the is of how XXX types, you in wide study commercial your and the tell opportunity significantly could on see you developed forward? being thoughts Given checkpoint-resistant the a us program strategy variety that

Yung Chyung

Yes.

So on question the first on for escalation. update dose the

So yes, on update progress so anticipating dose quarter, the we're escalation. for any in in fourth

process. And that limit So far the major dose how that obviously, in sure words, include safety would we've in making along dosing. signals no gotten that will other there's escalation

a Part the as be given point been In this Part starting are terms date, I and will out dose that staggered. escalation, we've of, thing to one AX we reminder, we progress do quarter. the should AX is observing anticipate, combo AX,

in seeing, heading escalation seeing we Part of so at safety year B data in towards anticipate with fourth quarter, of and first next of response of a clinical goal sort quarter expectations of stand we And in initiating providing updates XXXX. the where dose some

Tony Kingsley

James. Is Tony. Thanks, This

a it our look, strategy, us. therapy. of is need use you that reasonable, on and could So across we it and it Having We prove here. tumor There's be could X let's the exploring use mean, ahead it be I to We'll case think the obviously drug, performs trial backbone DRAGON multiple if thinking commercial as could, be types. across said clear, task what's this multiple inhibitors. checkpoint that, is

exciting possibilities. an that's set So of

a start types. Is expand imagine resistance. primary add the there to like chance across could tumor to continue in checkpoint, et things you to You different cetera, start things

a there's big in to a way. to get exciting DRAGON and big, set attached really it we're kind one thinking some But about So commercial with plan here this start get exciting a to possibilities of efficacy. potentially very of of development that. job is done But

Operator

Madhu the Kumar question Baird. Our from next of comes from line

Madhu Kumar

the big about with kind question start we'll SRK-XXX. of picture So

have the you dose So escalation dose these, you and expansion got the cohorts.

So kind this broadly to of looking I-O is, test your of to do kind more collaboration with versus a array partner a or XXX in inhibition broader question own on the in of the TGFß far kind a how really Tony big you for studies? go drug combination kind of of

Tony Kingsley

Yes. Thank you. question. Good

development certainly timing, Look, from a discussions would open look, position is. for product and out, is a big So And clinical question this very it's be, to is a and a those want in all on partnering to take strength. with obviously, think there's We it as given potential a engage space as in oncology big would laid I drug to naturally this size I which potential of space. lot more you be committed of the in be of how oncology ways of to just big a the development. the

and proof do a have to some ahead add task we of funds us, think concept. have some it and I we value to of get some

partnering. and enabling effort. checkpoint consider people there a this whole what the a we're doing certainly lot it's we'll space interesting. This lot people, in interested in because are can it And of of of is, big lot So a players to be

time. So very open to that, but the question is the right

first strengthen generate hand hand. our more is to our data think some at task I and

Madhu Kumar

Scholar Rock Holding (SRRK) 12 Aug 202020 Q2 Earnings call transcript